Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics
  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • News
    • Press Releases
  • Careers
Contact
  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • News
    • Press Releases
  • Careers

Press Releases

Sensei Biotherapeutics to Present Clinical Data at Upcoming Oncology Medical Conferences

Press ReleaseBy Sensei TeamOctober 9, 2018
Details

Sensei Biotherapeutics Appoints Ildiko Csiki, M.D., Ph.D., as Chief Medical Officer

Press ReleaseBy Sensei TeamAugust 21, 2018
Details

Sensei Biotherapeutics Reports New Data from Phase 1 Clinical Trial of SNS-301

Press ReleaseBy Sensei TeamJune 5, 2018
Details

Sensei Biotherapeutics Appoints John Celebi as President and Chief Executive Officer

Press ReleaseBy Sensei TeamMay 16, 2018
Details
123
Blog Topics
  • Featured(1)
  • Presentation(3)
  • Press Release(24)
  • Publication(16)
  • Recent(1)
Recent Posts
  • Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform
  • SITC Safety and Efficacy
  • Refractory Head and Neck Cancer Enrollment Update
  • SITC TIP
  • Iwagami Y et al. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon. 2017, PMID: 28971150
About

We are a clinical-stage immunotherapy company engaged in the discovery and development of next generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.

Contact
Headquarters
1405 Research Blvd, Suite 125
Rockville, MD 20850
Phone No
phone

+1.240.243.8000

Boston R&D Location
Smart Labs, Seaport District
6 Tide Street
Boston, MA 02210
Email
phone

info@senseibio.com

© 2021 Sensei Biotherapeutics. All Rights Reserved.
  • Privacy Policy
Footer
Go to Top